Novel dendritic cell-based vaccination in late stage melanoma

Abstract

Dendritic cells (DCs) are professional antigen-presenting cells (APCs) that play an important role in stimulating an immune response of both CD4⁺ T helper cells and CD8⁺ cytotoxic T lymphocytes (CTLs). As such, DCs have been studied extensively in cancer immunotherapy for their capability to induce a specific anti-tumor response when loaded with tumor antigens. However, when the most relevant antigens of a tumor remain to be identified, alternative approaches are required. Formation of a dentritoma, a fused DC and tumor cells hybrid, is one strategy. Although initial studies of these hybrid cells are promising, several limitations interfere with its clinical and commercial application. Here we present early experience in clinical trials and an alternative approach to manufacturing this DC/tumor cell hybrid for use in the treatment of late stage and metastatic melanoma.

Keywords:

• adjuvant
• cancer vaccine
• dendritic cell
• melanoma

Disclosure of Potential Conflicts of Interest

E.J.S. has no conflict interests. However, the employment of T.E.W. as Chief Executive Officer of Perseus PCI and G.E.P. as a consultant are relevant to the conflict of interest disclosure.